Sign up to our newsletter Subscribe
New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?

Sign up to our newsletter Subscribe
As more and more medicines come to market with multiple indications or the unrealised potential to treat multiple indications, the way we pay for those medicines becomes critical in making sure we can benefit from them. Indication-based pricing (IBP) permits price to vary according to indication and has been proposed to tackle this issue.
An error has occurred, please try again later.